|
|
|
|
 Peter Collins,
Vice President Pharma Business Development QIAGEN Peter Collins has over 25 years experience in the diagnostics industry, specialising in Companion Diagnostics in the targeted oncology market. As Vice President Pharma Business Development Peter heads a global team driving the uptake of personalized healthcare solutions in partnership with the pharma industry.
Previous to the acquisition of DxS by QIAGEN in September 2009, Peter was Senior Vice President Business Development, playing a pivotal role in securing a number of the company’s companion diagnostic agreements with key pharma clients including Amgen and Bristol Myers Squibb / Imclone Systems, Boehringer Ingelheim, Pfizer and AstraZeneca. As Vice President of Marketing and Sales for Vysis Europe (Abbott Molecular Diagnostics), Peter was responsible for strategy and delivery of PathVysion Her 2, a product used to select breast cancer patients eligible for Herceptin.
Peter has held senior executive roles at a number of early stage diagnostics and life sciences companies including Quantase (Biorad), Gentronix, Biogenex and Pronostics.
Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 10.10am The K-RAS Story: A case study in Pharma partnering for Drug-Diagnostic co-development
- Leading the new healthcare revolution in oncology: clinical biomarkers and targeted cancer therapies
- K-RAS and Amgen’s Vectibix® (panitumumab) for the treatment of metastatic colorectal cancer – the first partnership of its kind
- Regulatory hurdles and lessons learned
- The QIAGEN Companion Diagnostic Development Program
Peter Collins, Vice President Pharma Business Development,
QIAGEN 10.30am Panel discussion: strategies for development, approval and reimbursement of cancer diagnostics in conjunction with targeted therapies
- The challenge: both the diagnostic and the drug must be approved and reimbursed.
- Considering the options for pharma companies in diagnostic development – internal development, external partnerships or outsourcing?#
- Strategies for overcoming regulatory and reimbursement concerns – who needs to make the initial investment? What are the regulatory considerations? Who ultimately pays for a diagnostic test?
Peter Collins, Vice President Pharma Business Development,
QIAGEN President Molecular Diagnostics,
Abbott Molecular Senior Director and Global Head of Diagnostics,
Pfizer Global R&D Vice President Scientific and Medical Affairs,
Veridex (a Johnson & Johnson compnay) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
